ArticleCancers2021

The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.

Francesca Ligorio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.